In this episode, we explore Cognaize's recent funding achievement of $18M, delving into their impactful strides and innovations within the finance sector utilizing AI.

In this episode, we explore Meta's daring initiative in unveiling an open innovation AI research community, discussing its implications and the controversies surrounding this unprecedented move in the tech industry.

In this episode, we unravel an intriguing AI model that formulates hypotheses about extraterrestrial life and forecasts potential discoverers, shedding light on the captivating realm of scientific inquiry into alien existence.

In this episode, we delve into the major update of Google's Bard, a groundbreaking tool enabling the coding of applications directly from image screenshots, revolutionizing app development processes with an intuitive approach.

In this episode, we explore the profound impact of Hollywood's protest against AI actor cloning, discussing how this move has triggered major disruptions in the movie industry, potentially reshaping the future of filmmaking and the role of AI-generated actors.

In this episode, we delve into the unveiling of Meta's CM3leon AI, a groundbreaking innovation that promises to redefine the AI landscape, offering insights into its features, capabilities, and potential impact across various domains.

In this episode, we explore the seismic impact of AI on customer service, examining how AI-driven sales calls and chatbots are contributing to the potential elimination of 90% of jobs in this industry and the broader implications for businesses and employment.

In this episode, we discuss Meta's anticipated launch of a paid competitor to OpenAI's ChatGPT, exploring its potential impact on the landscape of AI-powered conversational agents and the broader implications for users and businesses.

In this episode, we delve into the partnership between the Associated Press and OpenAI, discussing the potential impact on journalism and the evolving role of AI in shaping news reporting.

In this episode, we delve into Nvidia's substantial $50 million investment in Recursion, exploring the implications and potential advancements in AI-powered drug discovery this partnership could yield.